Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABP 234 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| ABP 234 | EXPERIMENTAL | Participants will receive ABP 234 every 3 weeks (Q3W) for up to 12 months. |
| Pembrolizumab | ACTIVE_COMPARATOR | Participants will receive pembrolizumab Q3W for up to 12 months. |
| Pembrolizumab (US) | EXPERIMENTAL | Part 1: Participants will receive FDA-licensed pembrolizumab followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive FDA-licensed pembrolizumab followed by pemetrexed. |
| Pembrolizumab (EU) | EXPERIMENTAL | Part 1: Participants will receive EU-approved pembrolizumab followed by pemetrexed administered with platinum-based chemotherapy (cisplatin or carboplatin). Part 2: Participants will receive EU-approved pembrolizumab followed by pemetrexed. |
| Name | Type | Description |
|---|---|---|
| ABP 234 | DRUG | Administered by intravenous (IV) injection. |
| Pembrolizumab | DRUG | Administered by IV injection. |
| Pembrolizumab (US) | DRUG | Intravenous administration |
| Pembrolizumab (EU) | DRUG | Intravenous administration |
Inclusion Criteria: * Males and females ≥ 18 years of age. * Pathological diagnosis of non-squamous NSCLC. * Stage IB (T2 ≥ 4 cm), II, or IIIA NSCLC after complete surgical resection and received platinum-based chemotherapy. * For programmed death-ligand 1 (PD-L1) testing, tumor tissue from the res...
ABP 234 is an investigational small molecule being developed for early-stage non-squamous non-small cell lung cancer (NSCLC) and advanced or metastatic non-squamous NSCLC. It is being studied as a potential treatment for these conditions in clinical trials.
ABP 234 is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with non-squamous non-small cell lung cancer.
ABP 234 is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 3 trials are designed to compare ABP 234 with Keytruda (pembrolizumab) in patients with non-squamous non-small cell lung cancer.
ABP 234 is being studied in two Phase 3 clinical trials. The first, NCT06311721, compares ABP 234 with Keytruda in 315 participants with advanced or metastatic non-squamous NSCLC. The second, NCT06430866, assesses pharmacokinetic similarity between ABP 234 and Keytruda in 163 participants with early-stage non-squamous NSCLC.
ABP 234 is not the same as Keytruda (pembrolizumab). It is being studied as a potential biosimilar to Keytruda, meaning it is designed to be similar in terms of safety and efficacy. Clinical trials are comparing ABP 234 directly with Keytruda to evaluate their similarity in treating non-squamous non-small cell lung cancer.